Frisoni GB, Altomare D, Thal DR, Ribaldi F, van der Kant R, Ossenkoppele R, Blennow K, Cummings J, van Duijn C, Nilsson PM et al (2022) The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nat Rev Neurosci 23:53–66. https://doi.org/10.1038/s41583-021-00533-w

Article  CAS  PubMed  Google Scholar 

Selkoe DJ, Hardy J (2016) The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol Med 8:595–608. https://doi.org/10.15252/emmm.201606210

Article  CAS  PubMed  PubMed Central  Google Scholar 

Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M, Holtta M, Rosen C, Olsson C, Strobel G et al (2016) CSF and blood biomarkers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. Lancet Neurol 15: 673–684. https://doi.org/10.1016/S1474-4422(16)00070-3

Bridel C, Somers C, Sieben A, Rozemuller A, Niemantsverdriet E, Struyfs H, Vermeiren Y, Van Broeckhoven C, De Deyn PP, Bjerke M et al (2022) Associating Alzheimer’s disease pathology with its cerebrospinal fluid biomarkers. Brain 145:4056–4064. https://doi.org/10.1093/brain/awac013

Article  PubMed  Google Scholar 

Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, Morris JC, McKeel DW Jr., Farlow M, Weitlauf SL et al (2003) Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 60:1696–1702. https://doi.org/10.1001/archneur.60.12.1696

Article  PubMed  Google Scholar 

Grothe MJ, Moscoso A, Ashton NJ, Karikari TK, Lantero-Rodriguez J, Snellman A, Zetterberg H, Blennow K, Scholl M, Alzheimer’s Disease Neuroimaging Initiative (2021) Associations of fully automated CSF and novel plasma biomarkers with Alzheimer Disease neuropathology at autopsy. Neurology 97:e1229–1242. https://doi.org/10.1212/WNL.0000000000012513

Article  CAS  PubMed  PubMed Central  Google Scholar 

Irwin DJ, McMillan CT, Toledo JB, Arnold SE, Shaw LM, Wang LS, Van Deerlin V, Lee VM, Trojanowski JQ, Grossman M (2012) Comparison of cerebrospinal fluid levels of tau and abeta 1–42 in Alzheimer disease and frontotemporal degeneration using 2 analytical platforms. Arch Neurol 69:1018–1025. https://doi.org/10.1001/archneurol.2012.26

Article  PubMed  PubMed Central  Google Scholar 

Mattsson-Carlgren N, Grinberg LT, Boxer A, Ossenkoppele R, Jonsson M, Seeley W, Ehrenberg A, Spina S, Janelidze S, Rojas-Martinex J et al (2022) Cerebrospinal fluid biomarkers in autopsy-confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration. Neurology 98:e1137–e1150. https://doi.org/10.1212/WNL.0000000000200040

Article  CAS  PubMed  PubMed Central  Google Scholar 

Morimoto S, Takao M, Hatsuta H, Nishina Y, Komiya T, Sengoku R, Nakano Y, Uchino A, Sumikura H, Saito Y et al (2017) Homovanillic acid and 5-hydroxyindole acetic acid as biomarkers for dementia with Lewy bodies and coincident Alzheimer’s disease: An autopsy-confirmed study. PLoS One 12:e0171524. https://doi.org/10.1371/journal.pone.0171524

Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, Blennow K, Soares H, Simon A, Lewczuk P et al (2009) Cerebrospinal fluid biomarker signature in Alzheimer’s disease neuroimaging initiative subjects. Ann Neurol 65:403–413. https://doi.org/10.1002/ana.21610

Article  CAS  PubMed  PubMed Central  Google Scholar 

Strozyk D, Blennow K, White LR, Launer LJ (2003) CSF abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60:652–656. https://doi.org/10.1212/01.wnl.0000046581.81650.d0

Article  CAS  PubMed  Google Scholar 

Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttila T (2009) Cerebrospinal fluid beta-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66:382–389. https://doi.org/10.1001/archneurol.2008.596

Article  PubMed  Google Scholar 

Toledo JB, Brettschneider J, Grossman M, Arnold SE, Hu WT, Xie SX, Lee VM, Shaw LM, Trojanowski JQ (2012) CSF biomarkers cutoffs: the importance of coincident neuropathological diseases. Acta Neuropathol 124:23–35. https://doi.org/10.1007/s00401-012-0983-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Toledo JB, Cairns NJ, Da X, Chen K, Carter D, Fleisher A, Householder E, Ayutyanont N, Roontiva A, Bauer RJ etal (2013) Clinical and multimodal biomarker correlates of ADNI neuropathological findings. Acta Neuropathol Commun 1:65. https://doi.org/10.1186/2051-5960-1-65

Article  PubMed  PubMed Central  Google Scholar 

Jack CR Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J et al (2018) NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement 14:535–562. https://doi.org/10.1016/j.jalz.2018.02.018

Barthelemy NR, Li Y, Joseph-Mathurin N, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, Fagan AM, Perrin RJ, Goate AM et al (2020) A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease. Nat Med 26:398–407. https://doi.org/10.1038/s41591-020-0781-z

Mattsson-Carlgren N, Andersson E, Janelidze S, Ossenkoppele R, Insel P, Strandberg O, Zetterberg H, Rosen HJ, Rabinovici G, Chai X et al (2020) Abeta deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer’s disease. Sci Adv 6:eaaz2387. https://doi.org/10.1126/sciadv.aaz2387

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sato C, Barthelemy NR, Mawuenyega KG, Patterson BW, Gordon BA, Jockel-Balsarotti J, Sullivan M, Crisp MJ, Kasten T, Kirmess KM et al (2018) Tau Kinetics in Neurons and the Human Central Nervous System. Neuron 97:1284–1298 e1287. https://doi.org/10.1016/j.neuron.2018.02.015

Suarez-Calvet M, Karikari TK, Ashton NJ, Lantero Rodriguez J, Mila-Aloma M, Gispert JD, Salvado G, Minguillon C, Fauria K, Shekari M et al (2020) Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer’s continuum when only subtle changes in Abeta pathology are detected. EMBO Mol Med 12:e12921. https://doi.org/10.15252/emmm.202012921

Article  CAS  PubMed  PubMed Central  Google Scholar 

Murayama S, Saito Y (2004) Neuropathological diagnostic criteria for Alzheimer’s disease. Neuropathology 24:254–260. https://doi.org/10.1111/j.1440-1789.2004.00571.x

Article  PubMed  Google Scholar 

Irwin DJ, Xie SX, Coughlin D, Nevler N, Akhtar RS, McMillan CT, Lee EB, Wolk DA, Weintraub D, Chen-Plotkin A et al (2018) CSF tau and beta-amyloid predict cerebral synucleinopathy in autopsied Lewy body disorders. Neurology 90:e1038–e1046. https://doi.org/10.1212/WNL.0000000000005166

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kanemaru K, Kameda N, Yamanouchi H (2000) Decreased CSF amyloid beta42 and normal tau levels in dementia with Lewy bodies. Neurology 54:1875–1876. https://doi.org/10.1212/wnl.54.9.1875

Article  CAS  PubMed  Google Scholar 

Noguchi M, Yoshita M, Matsumoto Y, Ono K, Iwasa K, Yamada M (2005) Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci 237:61–65. https://doi.org/10.1016/j.jns.2005.05.015

Article  CAS  PubMed  Google Scholar 

Schirinzi T, Sancesario GM, Di Lazzaro G, Scalise S, Colona VL, Imbriani P, Mercuri NB, Bernardini S, Lang AE, Pisani A (2018) Clinical value of CSF amyloid-beta-42 and tau proteins in Progressive Supranuclear Palsy. J Neural Transm (Vienna) 125:1373–1379. https://doi.org/10.1007/s00702-018-1893-1

Article  CAS  PubMed  Google Scholar 

van Steenoven I, van der Flier WM, Scheltens P, Teunissen CE, Lemstra AW (2019) Amyloid-beta peptides in cerebrospinal fluid of patients with dementia with Lewy bodies. Alzheimers Res Ther 11:83. https://doi.org/10.1186/s13195-019-0537-5

Article  PubMed  PubMed Central  Google Scholar 

Kawarabayashi T, Nakamura T, Miyashita K, Fukamachi I, Seino Y, Shoji M (2020) Novel ELISAs to measure total and phosphorylated tau in cerebrospinal fluid. Neurosci Lett 722:134826. https://doi.org/10.1016/j.neulet.2020.134826

Article  CAS  PubMed  Google Scholar 

Kurihara M, Komatsu H, Sengoku R, Shibukawa M, Morimoto S, Matsubara T, Arakawa A, Orita M, Ishibashi K, Mitsutake A et al (2023) CSF P-Tau181 and other biomarkers in patients with neuronal intranuclear inclusion disease. Neurology 100:e1009–e1019. https://doi.org/10.1212/WNL.0000000000201647

Article  CAS  PubMed  PubMed Central  Google Scholar 

Matsubara T, Kameyama M, Tanaka N, Sengoku R, Orita M, Furuta K, Iwata A, Arai T, Maruyama H, Saito Y et al (2022) autopsy validation of the diagnostic accuracy of (123)I-Metaiodobenzylguanidine myocardial scintigraphy for Lewy Body Disease. Neurology 98:e1648–e1659. https://doi.org/10.1212/WNL.0000000000200110

Saito Y, Ruberu NN, Sawabe M, Arai T, Kazama H, Hosoi T, Yamanouchi H, Murayama S (2004) Lewy body-related alpha-synucleinopathy in aging. J Neuropathol Exp Neurol 63:742–749. https://doi.org/10.1093/jnen/63.7.742

Article  PubMed  Google Scholar 

Saito Y, Ruberu NN, Sawabe M, Arai T, Tanaka N, Kakuta Y, Yamanouchi H, Murayama S (2004) Staging of argyrophilic grains: an age-associated tauopathy. J Neuropathol Exp Neurol 63:911–918. https://doi.org/10.1093/jnen/63.9.911

Article  PubMed  Google Scholar 

Tanei ZI, Saito Y, Ito S, Matsubara T, Motoda A, Yamazaki M, Sakashita Y, Kawakami I, Ikemura M, Tanaka S et al (2021) Lewy pathology of the esophagus correlates with the progression of Lewy body disease: a Japanese cohort study of autopsy cases. Acta Neuropathol 141:25–37. https://doi.org/10.1007/s00401-020-02233-8

Article  PubMed  Google Scholar 

Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E et al (2012) National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement 8:1–13. https://doi.org/10.1016/j.jalz.2011.10.007

Article  PubMed  Google Scholar 

Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, Mirra SS et al (2012) National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach. Acta Neuropathol 123:1–11. https://doi.org/10.1007/s00401-011-0910-3

Article  CAS  PubMed  Google Scholar 

Dickson DW, Braak H, Duda JE, Duyckaerts C, Gasser T, Halliday GM, Hardy J, Leverenz JB, Del Tredici K, Wszolek ZK et al (2009) Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria. Lancet Neurol 8:1150–1157. https://doi.org/10.1016/S1474-4422(09)70238-8

Article  CAS  PubMed  Google Scholar 

McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG et al (2017) Diagnosis and management